Unlocking Upstream Value: Donor-To-Dose Solutions For Scalable Cell Therapy Manufacturing

Experts from Excellos, Lonza, and Akadeum share a deep dive into how decisions made early in the process—from donor sourcing and apheresis processing to cell selection technologies and automated manufacturing—directly affect therapeutic performance, regulatory approval, and clinical results.

This session explores the science, tools, and partnerships needed to create complete, patient-focused CGT solutions. The discussion features real-world examples and practical strategies to help both new and established therapy developers scale their operations more intelligently. Topics range from gaining early insights through donor characterization to reducing manufacturing variability with new cell separation technologies.

Key Takeaways

• Discover how the biology of the donor and the variability of starting materials influence downstream manufacturing results for cell therapies.
• Learn how modern cell selection technologies can boost purity, recovery, viability, and scalability.
• Find out how a strong manufacturing platform can improve therapeutic performance, lower COGS, and enable efficient scaling.
• Understand how collaboration among sourcing, process development, and manufacturing teams can add value throughout the entire CGT process.